




RealRate

PHARMACEUTICAL 2021

Histogen Inc
Rank 317 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Histogen Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Histogen Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 117% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	8,400
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,785
Liabilities, Non-Current	4,828
Other Assets	6,342
Other Compr. Net Income	0
Other Expenses	8,220
Other Liabilities	487
Other Net Income	41
Other Revenues	2,059
Property and Equipment	271
Research and Development	6,219
Selling, General and Administrative Expense	6,586

Output Variable	Value in 1000 USD
Assets	15,013
Liabilities	8,100
Expenses	21,025
Revenues	2,059
Stockholders Equity	6,913
Net Income	-18,925
Comprehensive Net Income	-18,925
BaseVar	23,119
ECR before Limited Liability	-33%
Economic Capital Ratio	140%